

OncoTherapy Science, Inc.

September 1, 2020

The press release from Kindai University regarding Phase II cancer-specific peptide vaccine therapy (investigator-initiated clinical trial) for esophageal cancer patients

OncoTherapy Science, Inc. (President & CEO: Jae-Hyun Park; hereinafter, “OncoTherapy”) today announces that a research group at Kindai University has issued a press release about publication of the article regarding Phase II adjuvant cancer-specific vaccine therapy for esophageal cancer patients curatively resected after preoperative therapy with pathologically positive nodes. OncoTherapy is the patent holder of the peptides used in this study as cancer-specific therapeutic vaccine.

Researchers (Prof. Takushi Yasuda et al.) at Kindai University have conducted a Phase II clinical study for esophageal cancer (esophageal squamous cell carcinoma (ESCC); which is the subtype of 95% esophageal cancer in Japan) patients with pathological lymph node metastasis who underwent preoperative therapy followed by surgery. The vaccine treated group showed a significantly higher 5-year esophageal cancer-specific survival than the control group. The manuscript has been published online in Annals of Surgery.

https://journals.lww.com/annalsofsurgery/Abstract/9000/Phase_II_Adjuvant_Cancer_specific_Vaccine_Therapy.94246.aspx

For more detail about the press release from Kindai University, please refer to the website below.

<https://www.kindai.ac.jp/news-pr/news-release/2020/08/029991.html> (in Japanese)